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tics. Results: 1534 eligible RA patients were assessed; Mono: 428 (28%), Combo: 
1106 (72%). Patient characteristics (Mono/Combo) included: age 51.8/51.7; female 
71%/75%; weight 68.6/68.5kg; top three comorbidities: dyslipidemia (16%/19%), depres-
sion/anxiety (9%/13%), obesity (8%/12%). Time since diagnosis: 68.6/78.2mo. Current 
line of biologic therapy: first-line 86%/75%, second-line 11%/18%, ≥ third-line 3%/6%. 
Top four biologics used across the two patient groups: etanercept (33%)/adalimumab 
(30%)/tocilizumab (9%)/certolizumab pegol (7%). Current lab values/disease severity 
measures: ESR (mm/h) 21.7/23.2; CRP (mg/l) 10.3/10.3; rheumatoid factor (positive) 
84%/87%; anti-CCP (positive) 70%/80%; current disease stage per physician judg-
ment: mild 65%/52%, moderate 32%/40%, severe 3%/8%; mean VAS 3.4/3.6; mean HAQ 
1.4/1.1; mean DAS 28 3.6/3.3; mean tender joint count 3.5/4.1; mean swollen joint 
count 2.4/2.6. ConClusions: In this cohort of RA patients in Europe, the majority 
of patients on monotherapy and combination therapy had mild disease per physi-
cian judgment and were on first-line biologic therapy. Lab measures and joint counts 
indicated only slightly higher disease burden among combination therapy patients. 
The impact of specific biologic treatments on observed patterns and the need for 
therapeutic sequencing may warrant further research.
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objeCtives: In Europe, biosimilars of complex molecules such as monoclonal 
antibodies have started to enter the market. In this research we aim to provide an 
understanding of the current expectations for the purchasing of these products 
as well as an overview of the tools that payers expect to employ to encourage bio-
similar use. Methods: Qualitative survey of payers across national, regional and 
local levels in France, Germany, Italy, Spain, the UK and Netherlands. Collection and 
analysis of data on (1) current and future attitudes relative to expected biosimilar 
purchasing systems; and (2) the tools that payers expect to use to drive biosimilar 
use, assuming this is a payer goal. Results: (1) The method of biosimilar purchase 
in the short term will vary by country, with the majority of countries using tenders 
to procure these products; (2) While tenders restricting choice of product to a single 
winner will not be used extensively in the short term, these will be common across 
most countries in the future; (3) Payers will also use a number of other tools such 
as formal and informal recommendations, prescription incentives and auditing or 
prescription targets in order to encourage use of the product they have chosen; (4) 
New procurement pathways and tools are being developed to introduce biosimilars, 
as highlighted by the new biosimilar law in Italy which defines a level of discount 
at the national level. ConClusions: Payer strategies should maximize savings by 
introducing less expensive biosimilars, but also must consider physician prefer-
ences, especially when influenced by potentially valid concerns about lack of data. 
In order to do this, payers are creating novel purchasing frameworks and tools, and 
while they are currently reticent to use restrictive methods to encourage use of 
biosimilars, this is expected to rapidly change in a short timeframe.
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objeCtives: Despite Ontario’s universal health care system, differences exist 
in health care accessibility and quality across the province. The objective of this 
study is to assess health care resource utilization for patients with ankle sprains 
based on rurality. Methods: Data on individuals who sought medical attention 
for ankle sprains between 2003 and 2011 in Ontario were obtained from multiple 
databases linked through the Institute for Clinical Evaluative Sciences (ICES). The 
Rurality Index of Ontario (RIO) was used to measure the rurality level of patients 
based on their population density and geographic distance to health care facili-
ties. Demographic characteristics were obtained for each of five RIO categories. 
Health care utilization (number of visits to primary care physicians, specialists and 
ambulatory care) and physician billing costs were obtained and compared among 
the RIO categories. Results: Between 2003 and 2011, the Ontario Health Insurance 
Program was billed $64 million and $36 million (2013 CAD) by specialists and gen-
eral practitioners, respectively, for the treatment of ankle sprains and dislocations. 
Approximately $116 million was spent on direct and indirect costs of emergency 
room visits for ankle sprains and dislocations. The largest proportion of rural inju-
ries occurred in the top income quintile. Patients in the most rural RIO category 
saw specialists least often and had the highest number of ambulatory care visits. 
However, specialist visits constituted higher costs when compared to GP visits. The 
highest specialist costs found were for males, elderly patients, and those who sought 
medical attention during winter. The observed statistical differences in cost of GP 
visits across RIO categories were not clinically meaningful. ConClusions: The 
differences in health care utilization between RIO categories may indicate a lack 
of access to specialist care with those residing in rural areas relying on emergency 
departments for care. These results may be useful in allocating future resources to 
better serve rural patients.
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with CZP in workplace and household productivity, and social participation were 
sustained up to 96 wks in PsA patients.
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objeCtives: With rising pressures on health care budgets, health technology 
assessment (HTA) agencies are increasingly scrutinizing medical devices (MDs) for 
economic benefits in addition to clinical benefits. This level of scrutiny has resulted 
in many unfavorable recommendations from agencies and only a small proportion 
of unconditionally favorable reviews. As an extension of our work reported at 2013 
ISPOR Annual Congress (Dublin, IR) this study aims to: 1) Identify key criteria cited 
by HTA agencies as major decision drivers, 2) Note common criteria among reviews 
that were positive, negative, or positive with reservations, and 3) Analyze tempo-
ral or geographic trends among decision drivers. Methods: A review of 68 HTAs 
and reimbursement decisions of implantable MD with a variety of indications was 
conducted, focusing on decisions published from 2008-2013 identified by Quintiles’ 
HTA Watch from North America, Europe, and Australia. Clinical, economic, and other 
factors noted as pivotal to HTA and reimbursement decisions were registered and 
compared. Importantly, care was exercised to note only the criteria that triggered 
a HTA to make a favorable or unfavorable decision, as opposed to criteria that were 
only correlative. Results: Key product attributes affecting HTA decisions include 
1) sufficiency and quality of evidence, 2) cost offsets and budget impact, 3) adverse 
event profiles, and 4) comparison to existing alternatives where available. Notab 
ly, 33% of HTA decisions were negative, with many decisions citing insufficient 
evidence. Additionally, a majority of favorable HTA decisions were reserved in their 
recommendations, citing a need for additional evidence to uphold the initially 
favorable recommendation. The relative importance of economic considerations 
varied across countries. ConClusions: HTA agencies’ scrutiny of sufficiency of 
evidence, among others, may significantly impact market access of medical devices. 
As such, manufacturers need careful planning to align evidence development, pric-
ing and access plans with HTA agency, payer and pricing authority requirements.
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objeCtives: The process of bringing a biosimilar to market in Europe is quicker, 
easier and cheaper than developing a new biologic. As a class, rheumatoid arthritis 
(RA) has the greatest number of anti-TNF biosimilar molecules in development, with 
more expected to follow. This research was focussed on the key issues reported by 
payers and Key Opinion Leaders (KOLs) in France, Germany and Italy. Methods: 
Supported by secondary research our study entailed conducting one hour tele-
phone interviews with influential senior payers involved in budgetary decision 
making at the national and regional level in addition to KOLs. These structured 
interviews explored how stakeholders perceived the introduction of anti-TNFs bio-
similars. Results: Payers see anti-TNF biosimilars as an opportunity to reduce the 
biologic budget but KOLs want to treat more patients within the same budget. Payers 
in Germany and France reported a greater perception of the efficacy of biosimilars 
than their counterparts in Italy. Treatment naïve patients are considered most suit-
able for anti-TNF biosimilars while automatic substitution was not favoured by 
any respondents. Nonetheless, price played a role and some KOLs stated they may 
attempt to switch existing patients who have a low risk of acute complications with 
very close monitoring. ConClusions: Biosimilars may be perceived unequally 
across markets. Manufacturers are likely to require the use of differentiated value 
stories when presenting their biosimilar products to payers and KOLs, with the latter 
more inclined to perceive them as an opportunity to treat more patients with the 
same expenditure instead of reducing budgets. Manufacturers will likely struggle 
to encourage the switching of existing patients onto biosimilars without offering a 
significant discount. In France and Germany, anti-TNF RA biosimilars are currently 
generating demand that closely matches their increasing prevalence.
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objeCtives: To assess the clinical characteristics of patients with RA who received 
biologic monotherapy (“Mono”) or biologic-containing combination therapy (“Combo”) 
in Europe. Methods: A multi-country, multi-center medical chart review study of 
patients with RA was conducted in Q42012 among physicians in hospitals and pri-
vate practices to collect de-identified data on patients who were recently treated 
with a biologic as part of usual care in France/Germany/Italy/Spain/UK. Physicians 
were screened for duration of practice (3-30yrs) and patient volume (≥ 2 RA biologic 
patients/week) and recruited from a large panel to be geographically representative 
in each country. Eligible patient charts (≥ 5) were randomly selected from among 
the patients visiting each center/practice during the screening period. Physicians 
abstracted date of diagnosis, treatment patterns/dynamics, and symptomatology/
disease status. Mono and Combo patients were compared used descriptive statis-
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objeCtives: Report baseline patient characteristics of the CAMPOS study, which 
is evaluating the PMO care map in Swiss clinical practice. Methods: Between 
June 2012„ŸMay 2013, specialist osteoporosis centers operating a DXA machine 
enrolled women diagnosed with PMO who initiated intravenous (IV) ibandronate 
or zolendronate, or subcutaneous (SC) denosumab (index date) within 6 months 
prior to center initiation. Study outcomes are recorded at index date (baseline) 
and any visit in the 24-month observation period thereafter, as available from rou-
tine practice. Results: Twenty-one centers, mainly in urban regions (81%), of a 
non-academic nature (76%), and specializing in rheumatology (71%), recruited 275 
women. Two-hundred-sixty-three met the inclusion criteria and were included in 
this baseline analysis; 180 (68%) of these received follow-up care at the specialist 
center and 83 (32%) were referred back to general practice. At baseline, mean (SD) 
age was 70.9 (9.7) years and mean time since diagnosis 5.4 (5.4) years (n= 248). The 
following diagnostic parameters and risk factors were assessed at the time of PMO 
diagnosis: prior osteoporotic fracture, 258 [94%] patients, with 60% reporting this 
risk factor; DXA bone mineral density (BMD) scan, 255 (97%) patients (hip and either 
lumbar spine or forearm BMD measured in 231 [88%] patients), mean (SD) BMD 
T-scores at the femoral neck and lumbar spine -2.34 (0.79; n= 230) and -2.89 (1.28; 
n= 232), respectively; calcium and vitamin D status, 260 (99%) patients; fracture 
history, 258 [98%] patients. ConClusions: In the current study, prevalent frac-
tures were assessed in almost all women initiating IV ibandronate or zolendronate, 
or SC denosumab, and the majority reported at least one prior fracture. Calcium 
and vitamin D status, DXA BMD scans and/or fracture history were also routinely 
assessed at PMO diagnosis.
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objeCtives: Osteoarthritis (OA) and the demand for OA care are increasing with 
the aging population. Policy-makers seek to identify policies to sustainably manage 
this growing demand, yet envisioning the short- and long-term effects of policy 
options is difficult within chronic care. We aimed to develop a decision-support 
tool enabling policy-makers to explore policies and their effects. Methods: We 
developed a system dynamics (SD) simulation of patient flow across the continuum 
of OA care in Alberta: from self-directed to primary and specialist care, through 
surgical interventions, post-surgical follow-up and subsequent re-operations. The 
simulation was developed using SD modeling principles and an iterative, integrated 
knowledge translation process, including multiple workshops with clinicians and 
administrators to define the problem, system boundaries and current patient flow. 
The resulting simulation was populated with data extracted from administrative 
databases (e. g. physician claims, inpatient records). Results: The model yields 
patient population, OA care resource requirements and associated cost results at 
each stage of care over 10 years by region and patient characteristics (e. g. sex). If 
current practices continue, annual hip and knee replacement surgery volumes are 
estimated to increase by more than 5,000 between 2015 and 2025. If a 14 week surgi-
cal wait-time is implemented in 2015, 600 additional surgeries must be performed 
in the first year to “catch-up” on the existing surgical queue, yet long-term surgery 
rates are similar to those without the wait-time target. The costs of the additional 
surgeries are partly offset by the savings achieved by fewer patients requiring care 
while awaiting surgery. ConClusions: This simulation can be used as a decision-
support tool to estimate changes in patient populations, resource requirements 
and costs over time that may result from various OA management scenarios. Such 
results can equip policy makers with additional evidence to make more informed 
OA care policy decisions.
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objeCtives: Osteoporosis is an important public health issue due to its rising preva-
lence and excess morbidity and mortality among this population. The present study 
aimed to demonstrate the use of clinical data repository in Israel’s second largest 
health organization (Maccabi Healthcare Services) to establish a registry of osteopo-
rosis patients and assess its early findings with respect to the epidemiology and bur-
den of the disease, high risk populations, and quality of care. Methods: Included 
in the registry are patients with history of osteoporosis diagnosis, typical fractures 
(e. g. closed fractures of proximal femur, vertebral, Colles’ and proximal humerus) 
and or purchases of relevant medications, documented since 2000. In addition, we 
included patients with low bone density from over 140,000 measurements, using an 
objeCtives: To estimate future scenarios of utilization of knee arthroplasty (KA) 
revision in the Spanish National Health System at the short and long term and its 
impact on primary KA utilization. Methods: A discrete event simulation model 
was built to represent the utilization of KA for 20 years (2011–2031) in the Spanish 
National Health System, especially the burden of KA revision according to differ-
ent scenarios of utilization and protheses survival. Data on KA utilization from 
1997 to 2011 was obtained from the Spanish Minimum Data Set. Three scenarios 
of future utilization of primary KA were estimated: 1) fixed number since 2011; 2) 
fixed age and sex adjusted rates since 2011; and 3) projection using a linear regres-
sion model. These three scenarios were combined with two prostheses survival 
functions L) from a study including primary KA from 1995 to 2000; and H) from 
the Catalan Registry of Arthroplasty, including primary KA from 2005 to 2013. The 
model was programmed using ARENA. The simulation results were analyzed at the 
short (2015) and long-term (2030). Results: Variations in the number of revisions 
depended on both the primary utilization rate and the survival function applied, 
ranging from 8.3% to 31.6% increase at the short-term and from 38.3% to 176.9% 
at the long term, percentages corresponding to the combinations of scenario 1 
(low primary utilization rate) and survival function H (better survival) versus sce-
nario 3 (high primary utilization rate) and survival function L (worse survival), 
respectively. The prediction of increase on overall surgeries ranged from 0.1% to 
22.3% at the short-term and from 3.7% to 98.2% at the long-term. ConClusions: 
Projections of the burden of knee arthroplasty provide a quantitative basis for 
future policy decisions relating to concentration of high complexity procedures, 
the number of orthopaedic surgeons required to perform these procedures and 
the number of resources needed.
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objeCtives: Cachexia is a medical syndrome associated with several chronic 
health conditions including many cancers, COPD, HIV, and kidney disease. 
Cachexia is a wasting type syndrome characterized as a loss in body mass or 
metabolic dysfunction. The loss in mass is associated with decreases in strength 
and functional capacity. Currently there is little research into cachexia and our 
objective is to characterize cachexia patients, their health care utilization and 
costs. Methods: For this study we utilized one year (2009) of the Nationwide 
Inpatient Sample (NIS). The NIS represents all inpatient stays at a random 20% 
sample of hospitals within the United States. We grouped cachexia individuals 
by primary or secondary diagnosis and then compared those with cachexia to all 
others in terms of length of stay (LOS) and total cost. Finally we looked into factor 
predicting increased LOS using a negative binomial model. Results: We esti-
mated US prevalence for cachexia related admissions at 161,898 cases. Cachexia 
patients were older with an average age of 67.95 versus 48.10 in their non-cachexia 
peers. Hospitalizations associated with cachexia had an increased LOS compared 
to non-cachexia patients (6 days versus 3) with average costs per stay $4,641.30 
greater. Differences were seen in loss of function (LOF) with cachexia patients 
mostly in the major LOF category (52.60%) whereas non-cachexia patients were 
spread between minor, moderate, and major LOF (36.28%, 36.11%, and 21.26%). 
Significant positive predictors of increased LOS among cachexia patients included 
urban hospital (IRR= 1.21 non-teaching urban, IRR= 1.23 teaching urban), having 
either major (IRR= 1.41) or extreme (IRR= 2.64) LOF, and having a primary diagnosis 
of pneumonia (IRR= 1.15). ConClusions: Cachexia is a diverse syndrome associ-
ated with a number of chronic diseases. We have characterized cachexia and seen 
it associated with increased length of stay, increased cost, and more severe loss 
of function compared to those without cachexia.
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objeCtives: To describe baseline characteristics and changes in BMD T-scores at 
1 year, in postmenopausal women with OP receiving 2 denosumab injections in 
routine clinical practice in Bulgaria. Methods: This retrospective observational 
study, conducted in 11 specialist (endocrinology or rheumatology) practices scat-
tered geographically across Bulgaria, included postmenopausal women ≥ 50 years 
old with a clinical diagnosis of OP, who initiated denosumab 60 mg Q6M on or after 
Oct 2011 (regulatory approval of denosumab in Bulgaria) and received a follow-up 
injection within 7 months (until Aug 2013). All study outcomes were recorded as per 
routine clinical practice/reimbursement requirements, with BMD T-scores recorded 
(at ≥ 1 site) at first denosumab injection (baseline) and 1-year follow-up. Descriptive 
statistics were conducted. Results: 222 women met the inclusion criteria with a 
mean (SD) age of 64.2 (±8.54) years; approximately half (49.5%) were < 65 years old 
and13.1% ≥ 75 years. Mean (SD) age at menopause was 48.1 (±3.98) years. 26.6% 
reported a prior fragility fracture, with vertebral the most common site (71.2%) 
followed by hip (6.8%) and other sites (32.2%, excluding hip). At baseline, 2.7% were 
receiving vitamin D only, 5.9% calcium supplements only and 35.1% both; 31.5% had 
received prior OP therapy. At baseline, mean (SD) BMD T-score was -3.2 (±0.63) at 
the lumbar spine (LS; n= 189), -2.3 (±0.81) at the total hip (TH; n= 75) and -2.7 (±0.71) 
at the femoral neck (FN; n= 137). At 1-year follow-up, all women had BMD assessed 
at ≥ 1 site; T-scores increased to -2.7 (±0.57) at the LS (n= 187), -2.1 (±0.91) at the TH 
(n= 65) and -2.4 (±0.68) at the FN (n= 123). ConClusions: Postmenopausal women 
with OP receiving 2 denosumab injections in Bulgarian clinical practice had a mean 
age of 64.2 years and experienced improved mean BMD T-scores at the LS, TH, and 
FN after 1 year. Study funded by Amgen.
